Kyoto Pharmaceutical University · Division of Microbiology and Infection Control · 講師

Research keywordsSARS-CoV-2 variants・neutralizing antibodies・spike protein epitopes・monoclonal antibodies・Omicron variants・Varicella zoster virus・Epstein-Barr virus・vaccine response・antiviral resistance・HSV-1 antiviral activity

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• SARS-CoV-2 BA.2.86 is susceptible to the neutralizing antibody MO11 targeting subdomain 1 despite the E554K mutation near the epitope.2025 · Journal of virology
• Epitopes of an antibody that neutralizes a wide range of SARS-CoV-2 variants in a conserved subdomain 1 of the spike protein.2024 · Journal of virology
• Single Amino Acid Substitution Within the Helicase of Varicella Zoster Virus Makes It Resistant to Amenamevir.2024 · Journal of medical virology
• Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population.2023 · Journal of infection and public health

• 新型コロナウイルス広域中和抗体の同定と中和メカニズムの解明2024 · 科学研究費助成事業
• 80歳以上高齢者に対するSARS-CoV-2ワクチン接種の有効性および有効期間解明2022 · 科学研究費助成事業
• 抗HSV-1活性を有する新規化合物の探索と開発2019 · 科学研究費助成事業

• Official profile